Cannabis M&A After Rescheduling: Are You Ready For What Comes Next?

Key Takeaways:

• The U.S. Department of Justice rescheduled state-licensed medical cannabis and FDA-approved cannabis products to Schedule III on April 23, 2026, marking a structural shift in federal tax and regulatory treatment.

• Cannabis rescheduling could accelerate M&A activity in 2026 and beyond by potentially improving cash flow, reopening equity markets, and reshaping buyer and seller expectations — though adult-use cannabis remains under review. 

• As capital returns, buyers will become more selective, prioritizing clean financials, defensible earnings, and clear visibility into tax and compliance risk.

—

The cannabis industry has entered a new regulatory phase. On April 23, 2026, the U.S. Department of Justice officially rescheduled state-licensed medical cannabis and FDA-approved cannabis products from Schedule I to Schedule III. This marks a significant shift in federal treatment of cannabis-related businesses and begins to reshape how the industry is taxed, financed, and valued.

However, the policy picture is not complete. The Drug Enforcement Administration (DEA) is scheduled to hold a new administrative hearing beginning June 29, 2026, focused on the proposed rescheduling of adult-use cannabis. That proceeding is expected to be an important factor in determining how far federal reform extends beyond medical and FDA-approved products.

These developments are already beginning to reshape how capital is deployed, how deals are underwritten, and how both buyers and sellers position themselves in a changing M&A environment. 

Medical Markets: Early Impact From Schedule III Rescheduling 

Medical cannabis markets are the first to experience direct impact from rescheduling. 

Medical-only states such as Florida and Pennsylvania may see early M&A traction as operators adjust to improved federal tax treatment and begin to reframe valuation expectations under Schedule III. In these markets, in which adult-use frameworks are not yet in place, rescheduling has a more direct and immediate effect on operating economics and deal modeling. 

The removal of 280E constraints for rescheduled activity improves cash flow visibility, making medical cannabis operators more attractive acquisition targets and more credible acquirers. 

Recent market developments illustrate how quickly these changes may influence capital formation. In June 2026, Trulieve became the first U.S. cannabis company approved to list on the New York Stock Exchange after completing a restructuring that separated its medical cannabis operations from markets serving both medical and adult-use customers. 

Recreational Markets: Awaiting Clarity From the DEA Process 

Adult-use cannabis remains the key unresolved variable in the federal rescheduling framework.

The DEA’s June 29, 2026, administrative hearing will be a pivotal moment for recreational markets. If adult-use cannabis moves toward Schedule III classification, it could significantly expand access to capital and accelerate M&A activity

If it does not, recreational cannabis will continue operating under a bifurcated structure — in which medical operators benefit from improved tax treatment while adult-use markets potentially remain more constrained.

Even in the current environment, recreational markets are expected to see gradual consolidation as capital conditions improve. Larger operators are expected to continue to pursue scale through acquisition, but selectively, with a strong focus on compliance history, margin durability, and operational efficiency. 

Distressed Asset Consolidation

Distressed consolidation is likely to remain a consistent theme across fragmented cannabis markets, particularly those with oversupply or tightening margins. In many cases, these transactions are driven more by operational stress than by policy changes, but rescheduling may accelerate buyer interest.

If You’re Considering a Sale, Preparation Is the Advantage 

If you see rescheduling as a potential exit window, preparation is where deals are won or lost. 

Build Financial and Reporting Credibility

Before a buyer ever makes an offer, they will expect clean, supportable financial information and a well-organized data room. Remediating historical books and records — and strengthening financial reporting through audits or reviews where appropriate — can materially affect valuation, structure, and deal execution speed. 

Think About Tax Strategy Early

Transaction structure drives tax outcomes. Understanding your options before you go to market can help you evaluate asset versus equity deals, address legacy 280E exposure, and avoid surprises late in negotiations. 

Use Quality of Earnings to Identify Potential Issues Early 

A Quality of Earnings (Q of E) analysis gives buyers a clearer view of normalized operating results — can strengthen your position in discussions with buyers. It allows you to identify add-backs, explain volatility, and defend your valuation with data instead of assumptions. 

If You’re a Buyer, Discipline Still Wins Deals 

Rescheduling may bring more opportunities, but it does not eliminate risk. For buyers, strong diligence and thoughtful structuring will be just as important. 

Financial and Tax Diligence

Understanding what you are really buying means digging into historical and projected earning, working capital needs, tax positions, and compliance history. These findings can directly affect pricing, escrow terms, and post-close strategy. 

Plan for Integration Before You Close

Post-deal integration is an area in which many cannabis transactions stumble. Aligning accounting systems, internal controls, and operational processes early can support more effective post-deal integration. 

Positioning Your Business for a Shifting Market

Even with Schedule III rescheduling in place for medical and FDA-approved cannabis, the industry remains in transition. State regulation still governs operations, and the outcome of the DEA’s adult-use hearing will shape the next phase of market normalization.

For both buyers and sellers, preparation remains the central theme. Gather documentation and conduct due diligence well in advance.